Fig. 7. BDA-366 decreases the phosphorylation of AKT and Bcl-2.
a Representative western blots of pAKT, tAKT, and Mcl-1 in OCI-LY-1 cells (LD50 for BDA-366: 0.32 μM) treated for 6 h with 0-0.6-1-3 µM BDA-366. Vinculin was used as a loading control. One representative experiment out of 3 performed is shown. b BDA-366 inhibits BCR-induced AKT and GSK3 phosphorylation in primary CLL cells. Cells were pretreated with BDA-366 (2 μM) for 90 min prior to being stimulated with immobilized anti-IgM (imm-aIgM) for 30 min (2 × 107 beads coated with 20 μg goat anti-human IgM antibody per 1 × 107 cells)34. c BDA-366 inhibits BCR-induced Mcl-1 upregulation and Bcl-2 phosphorylation in primary CLL cells. Cells were pretreated with BDA-366 (2 μM) as above and then stimulated for 24 h with imm-aIgM prior to harvesting for immunoblotting analysis.